Acute Heart Failure Pipeline Appears Robust With 10+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

DelveInsight's "Acute Heart Failure Pipeline Insight 2026" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the Acute Heart Failure pipeline landscape. It covers the Acute Heart Failure pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Acute Heart Failure pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Acute Heart Failure Pipeline? @ https://www.delveinsight.com/sample-request/acute-heart-failure-ahf-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=yash

Key Takeaways from the Acute Heart Failure Pipeline Report
• In August 2026, Tenax Therapeutics announced that its Phase III trial of an investigational heart-failure therapy failed to meet its primary endpoint of improving six-minute walk distance and also failed to demonstrate a benefit in patient-reported symptoms.
• In August 2026, Novo Nordisk continued development of ziltivekimab in heart failure despite the drug failing a separate late-stage cardiovascular outcomes trial, with ongoing heart-failure research expected to provide further data in 2027.
• DelveInsight's Acute Heart Failure Pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for Acute Heart Failure treatment.
• The leading Acute Heart Failure Companies such as Windtree Therapeutics, Adrenomed, Arena Pharmaceuticals, Bristol-Myers Squibb, Rockwell Medical Inc. and others.
• Promising Acute Heart Failure Therapies such as Finerenone, Dapagliflozin, Nesiritide (1+0.01), Relaxin, RLX030, sacubitril/valsartan (LCZ696), CXL01427 and others.

Want to know which companies are leading innovation in Acute Heart Failure? Dive into the full pipeline insights @ https://www.delveinsight.com/sample-request/acute-heart-failure-ahf-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=yash

The Acute Heart Failure Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Acute Heart Failure Pipeline Report also highlights the unmet needs with respect to the Acute Heart Failure.

Acute Heart Failure Overview
Acute heart failure (AHF), also known as acute decompensated heart failure or cardiac failure, is not a single disease entity, but rather a syndrome of the worsening of signs and symptoms reflecting an inability of the heart to pump blood at a rate commensurate to the needs of the body at normal filling pressure. AHF is often not acute in onset, typically developing gradually over the course of days to weeks, where the acuity is a function of the need for urgent or emergent therapy due to the severity of these signs or symptoms. AHF may be the result of a primary disturbance in the systolic or diastolic function of the heart or of abnormal venous or arterial vasoconstriction, but generally represents an interaction of multiple factors, including volume overload.

Acute Heart Failure Emerging Drugs Profile
• Istaroxime: Windtree Therapeutics
Istaroxime is a first-in-class, dual action, agent in clinical development for the treatment of acute decompensated heart failure (ADHF). Istaroxime's dual mechanism is designed to improve both systolic contractions of the heart as a potent positive inotropic agent that increases contractility through inhibition of Na+/K+-ATPase, as well as its diastolic myocardial relaxation through activation of the SERCA2a calcium pump on the sarcoplasmic reticulum.

• Adrecizumab: Adrenomed
The Company's lead product candidate is Adrecizumab (HAM8101; INN: enibarcimab), a clinical-stage, first-in-class drug targeting loss of vascular integrity. The strong rationale for Adrecizumab is supported by the elegance of its mode of action, a monoclonal antibody that on binding to its target Adrenomedullin preserves its functionality as regulator of vascular integrity.

If you're tracking ongoing Acute Heart Failure Clinical trials, this press release is a must-read @ https://www.delveinsight.com/sample-request/acute-heart-failure-ahf-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=yash

Acute Heart Failure Companies
Windtree Therapeutics, Adrenomed, Arena Pharmaceuticals, Bristol-Myers Squibb, Rockwell Medical Inc. and others.

The Acute Heart Failure Pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Acute Heart Failure with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Acute Heart Failure Treatment.
• Acute Heart Failure Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Acute Heart Failure Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Acute Heart Failure market.

Acute Heart Failure pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous

Acute Heart Failure Products have been categorized under various Molecule types such as
• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine

From emerging drug candidates to competitive intelligence, the Acute Heart Failure Pipeline Report @ https://www.delveinsight.com/sample-request/acute-heart-failure-ahf-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=yash

Scope of the Acute Heart Failure Pipeline Report
• Coverage- Global
• Acute Heart Failure Companies- Windtree Therapeutics, Adrenomed, Arena Pharmaceuticals, Bristol-Myers Squibb, Rockwell Medical Inc. and others.
• Acute Heart Failure Therapies such as Finerenone, Dapagliflozin, Nesiritide (1+0.01), Relaxin, RLX030, sacubitril/valsartan (LCZ696), CXL01427 and others.
• Acute Heart Failure Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Acute Heart Failure Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Discover what's next for the Acute Heart Failure Treatment landscape in this detailed analysis @ https://www.delveinsight.com/sample-request/acute-heart-failure-ahf-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=yash

Table of Contents
1. Introduction
2. Executive Summary
3. Acute Heart Failure: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Acute Heart Failure - DelveInsight's Analytical Perspective
7. Mid Stage Products (Phase II)
8. Istaroxime: Windtree Therapeutics
9. Drug profiles in the detailed report.....
10. Early Stage Products (Phase I)
11. Drug name: Company name
12. Drug profiles in the detailed report.....
13. Inactive Products
14. Acute Heart Failure Key Companies
15. Acute Heart Failure Key Products
16. Acute Heart Failure- Unmet Needs
17. Acute Heart Failure- Market Drivers and Barriers
18. Acute Heart Failure- Future Perspectives and Conclusion
19. Acute Heart Failure Analyst Views
20. Acute Heart Failure Key Companies
21. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.